BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations

We precocious compiled a database of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. BioMarin Pharmaceutical Inc. is among the champion worth stocks to put in.

TheFly reported connected March 16 that Wells Fargo maintained an Overweight standing connected BMRN with a $75 terms target. The steadfast noted that BioMarin discontinued 3 Phase 2 Voxzogo studies successful Turner Syndrome, SHOX-deficiency, and ACAN-deficiency owed to cases of Slipped Capital Femoral Epiphysis observed successful investigator-sponsored trials. Wells Fargo views the information hazard arsenic circumstantial to definite indications alternatively than the drug’s mechanism, and considers BMRN’s outlook little babelike connected Voxzogo. The steadfast indicated it remains supportive and sees the shares arsenic a buying accidental successful the lawsuit of terms weakness.

On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported affirmative caller results from ongoing objective trials and real-world studies of Voxzogo (vosoritide) successful children with achondroplasia. The findings item the benefits of aboriginal treatment, demonstrating sustained multi-year maturation improvements, enhanced assemblage proportionality, and accrued limb span compared to untreated children.

Analyses besides showed durable tallness gains, unchangeable arm-to-height ratios, and important improvements successful assemblage wide scale for those who began attraction earlier property two. Additional real-world information from patients successful Japan, Europe, and the U.S. volition beryllium presented astatine the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting successful Baltimore, reinforcing the established efficacy and information illustration of Voxzogo.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is simply a biotechnology institution that develops and commercializes therapies for uncommon familial diseases, including enzyme‑replacement and cistron therapies, improving attraction options for patients with serious, often life‑limiting conditions.

While we admit the imaginable of BMRN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.